Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250051/S001

Juveena Hydrogel System

Rejoni, Inc. · Decision date Oct 28, 2026

MEDTECHLEDGER EXPLANATIONP250051/S001

What did the FDA decide?

The FDA database records a 30-Day Notice for the Juveena Hydrogel System, submitted by Rejoni, Inc. The stated purpose is a change to remove visible particulates prior to final packaging. The supplement type is a Process Change involving the Manufacturer/Sterilizer/Packager/Supplier, and the decision is recorded as OK30.

This notice is not a new approval of the whole system and does not establish safety or clinical effectiveness. The device is classified as a barrier, absorbable, adhesion product under product code MCN in Obstetrics/Gynecology. The source statement does not specify the particulate removal method, the manufacturing stage affected, or any resulting performance data.

FDA approval order statement

a change to remove visible particulates prior to final packaging
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Obstetrics/Gynecology
Decision date
Oct 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250051/S001
Regulatory pathway
PMA supplement
Applicant
Rejoni, Inc.
Product code
MCN
Decision code
OK30
Decision date
Oct 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Barrier, absorbable, adhesion.

Applicant
Rejoni, Inc.
Product code
MCN
FDA device class
3

For the original device and its historical approval scope, see PMA P250051. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250051 · Original PMA

    Juveena Hydrogel System

  2. P250051/S001 received

    Application receipt date recorded by FDA.

  3. P250051/S001 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P250051. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250051

Product / regulatory recordCompanyPathwayDecision dateSource
Rejoni, Inc.PMA approvalSep 28, 2026FDA

Explore the linked device profile

Other records with product code MCN

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementNov 5, 2026FDA
Womed LeafP240015/S003
Womed SasPMA supplementOct 25, 2026FDA
Womed SasPMA approvalSep 9, 2025FDA
ETHICON, Inc.PMA approvalSep 15, 1989FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Rejoni, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Second Floor, Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records